Excellent post by F6 on Investor Village.

Hepalink continues to expand their USA presence with the purchase of Cytovance Biologics. I for one am very pleased that Hepalink has bought in to Resverlogix and that Resverlogix will benefit from their progressive developments and the kind of scientific knowledge, distribution and marketing they bring to RVX. This is a very interesting chess unfolding.

What we need now is management and communications competence at RVX.

Some people are making a big deal of the situation in the Chinese stock markets and that may well be true. However, I spent 26 years in the corporate world and when I look at Hepalink I do not believe the fact that it is not trading has anything to do with it's profitability and particularly at it's American division. Think long term.

Toinv

Here is the post. F6...hope you don't mind my repost.

<!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman"; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"Times New Roman"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin;} </style> <![endif]-->

GEN News Highlights
More »
Aug 24, 2015

Hepalink USA to Buy Cytovance Biologics for $205.68M+


Hepalink USA, the wholly owned U.S. subsidiary of Shenzhen Hepalink Pharmaceutical, will acquire the biopharmaceutical contract development manufacturing organization Cytovance® Biologics for $205.68 million cash plus additional contingent payments, Cytovance said today.

The deal adds a CDMO to Hepalink’s U.S. portfolio, which includes Scientific Protein Laboratories (SPL), a global supplier of active pharmaceutical ingredients (APIs). Hepalink and SPL together are one of the largest suppliers of heparin sodium API worldwide.

Cytovance specializes in cGMP production of therapeutic proteins and antibodies from mammalian cell culture, microbial fermentation, transgenic processes, and small-scale “flex suite” programs.

Cytovance also offers process development services, cell-line development, purification development, stability testing, and regulatory support services, all from its Oklahoma City facilities. Hepalink plans to retain Cytovance’s management and its 178 employees in the U.S.

“Hepalink will accelerate the realization of its strategy in the global macromolecule biopharmaceutical space. Cytovance will have the resources to expand its manufacturing capabilities, enhancing its ability in late stage clinical drug production and commercial business,” Li Li, Hepalink’s chairman and CEO, said in a statement. “We are very impressed with Cytovance's top-tier leadership team and will entrust this team to lead the future growth of the company.”

Cytovance added its own expansion plans will be accelerated as a result of Hepalink’s acquisition. Those plans include the addition of 5,000L and 10,000L mammalian reactors and 1,000L and 5,000L microbial fermenters, as well as increased analytical capabilities, process development and process characterization capabilities.

“This will expand our ability to develop and grow both our domestic and international businesses and to secure our current expansion plans in our Oklahoma City facilities,” added Cytovance President and CEO Darren Head. “We do not anticipate any changes in how we currently do business. We will become part of a very successful company that shares our commitment to safety and quality.”

Hepalink USA agreed to acquire 100% of the equity interest of Cytovance®. Upon consummation of the acquisition, Hepalink will hold 100% of the equity interest indirectly through Hepalink USA. The deal is expected to close in October following regulatory approval, at which point Cytovance® Biologics Inc. will become a fully consolidated subsidiary of Hepalink USA.

Established in 1998, Hepalink is publicly-traded on the Shenzhen Stock Exchange, and based at Shenzhen High-Tech Park.





http://www.genengnews.com/gen-news-highlights/hepalink-usa-to-buy-cytovance-biologics-for-205-68m/81251657/